Migraine Centers
- Company typePrivate
- Founded2011
- HeadquartersRichardson, United States
- Headcount51–100
- GTM typeB2C
- OfferingServices
Migraine Centers firmographics
Firmographics- Name
- Migraine Centers
- Legal name
- Migraine Centers, LLC
- Website
- https://migrainecenters.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Migraine Centers industry classification
Industry- Product category
- Migraine Treatment Services
- NAICS
- Other Ambulatory Health Care Services (6219)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Headache & Migraine Medicine (HLAKAIAE)
- akta.pro secondary industries
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Pain Management & Interventional Procedure Centers (HLAFAIAH), Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)
Keywords
Where Migraine Centers is headquartered
LocationHeadquarters
- HQ city
- Richardson
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Migraine Centers business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Medical Procedure Fees: Revenue generated from performing the Omega Procedure, including trial phase and permanent implant procedures. Insurance verification conducted during initial consultation to determine coverage and out-of-pocket costs.
- Insurance Billing: Accepted insurance plans include Aetna Commercial, Cigna Commercial, Blue Cross Blue Shield, Humana Commercial, Medicare A Texas, United Health Care, Tricare East, and self-pay options. Practice handles insurance verification and pre-authorization.
- Consultation Services: Revenue from initial consultations and follow-up appointments for device monitoring and adjustments. Follow-up includes stitch removal, recovery assessment, and system performance evaluation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Insurance-based treatment with variable out-of-pocket costs |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Migraine Centers product offering
Product offeringCore offering
Migraine Centers offers the Omega Procedure®, an FDA-approved neurostimulation therapy for chronic migraines. The treatment involves a two-phase approach: a Trial Phase with temporarily implanted leads (1-2 weeks) to assess efficacy, followed by a Permanent Phase implanting a small battery-powered neurostimulator beneath the skin near the occipital nerve. Patients activate electrical impulses via a remote control to disrupt migraine pain signals before reaching the brain.
Product overview
Migraine Centers offers a single unified treatment product: the Omega Procedure®, a neurostimulation therapy. The procedure involves two phases—a Trial Phase where leads are temporarily implanted to test effectiveness over 1-2 weeks, followed by a Permanent Phase where a battery-powered neurostimulator is implanted for long-term use. The device is controlled via an external remote control, allowing patients to activate electrical impulses that disrupt migraine pain signals. All services (initial consultation, pre-authorization, the trial and permanent implant procedures, follow-up care) are components of this single treatment offering.
Differentiator
Problem solved
Functional benefit
Products and services
- Omega Procedure® An FDA-approved neurostimulation therapy for chronic migraine sufferers that involves a two-phase treatment: a Trial Phase with temporarily implanted leads (1-2 weeks, four leads placed under the skin in a 45-minute outpatient procedure) to test efficacy, followed by a Permanent Phase implanting a battery-powered neurostimulator about the size of a silver dollar beneath the skin near the occipital nerve. The device is patient-activated via a handheld remote control to emit electrical impulses that disrupt migraine pain signals before reaching the brain. Targeted at individuals whose chronic migraines have not responded to medications, Botox, nerve blocks, physical therapy, or lifestyle changes.
Quantifiable outcome
- Nearly 90% success rate in those who trial the procedure
- +3 more outcomes
Companies that use Migraine Centers
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Migraine Centers technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Migraine Centers partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights4 records
Migraine Centers competitors and assessment
Company assessmentDirect peers
- Diamond Headache Clinic: Long-standing specialty headache clinic in Chicago focused on chronic migraine and intractable headache patients. Both organizations operate as specialty headache practices delivering interventional treatment to refractory patients, making it the closest operational peer to Migraine Centers.
- Jefferson Headache Center (Thomas Jefferson University): Academic specialty headache clinic providing advanced interventional and procedural migraine care. Comparable because both entities treat treatment-resistant chronic migraine patients with multi-modal, procedure-based therapies rather than primary pharmaceutical management.
Emerging players
- axioBionics: Developer of wearable and implantable neurostimulation devices focused on pain, migraine, and muscle disorders. Comparable as a smaller neuromodulation specialist operating in overlapping migraine and chronic pain indications.
- Axonics (Boston Scientific): Neuromodulation company (now part of Boston Scientific) with rechargeable sacral and spinal cord stimulators. Comparable on the neurostimulation device side, though focused on incontinence and chronic pain rather than migraine-specific indications.
- eNeura: Maker of the FDA-cleared single-pulse transcranial magnetic stimulation (sTMS) device for acute and preventive migraine. Targets the same chronic-migraine patient population with a non-invasive neuromodulation alternative.
- Theranica (Nerivio): Maker of Nerivio, an FDA-cleared, app-controlled remote electrical neuromodulation (REN) wearable for acute and preventive migraine. Directly competes with the Omega Procedure on the neuromodulation thesis for chronic migraine, but offers a non-invasive, prescription digital therapeutic alternative.
- Cefaly: Manufacturer of an FDA-cleared external trigeminal nerve stimulation (eTNS) device for migraine prevention and acute treatment. Comparable as a non-invasive neuromodulation option targeting the same refractory migraine patients, with the opposite go-to-market (consumer device vs. surgical service).
Broad incumbents
- Medtronic (Pain Therapies): Global medical device incumbent with Intellis and Vanta spinal cord stimulation and targeted drug delivery systems for chronic pain. Comparable because Medtronic powers much of the implant neurostimulation infrastructure that condition-headache specialists like Migraine Centers' physician background draws on.
- Mayo Clinic Headache Division: Large academic medical center with a dedicated headache/neurology division that treats refractory migraine patients. Comparable as a destination headache treatment provider, although embedded within a broader multi-specialty system rather than a focused single-procedure practice.
- Abbott (Proclaim Neurostimulation Systems): Major medical device manufacturer offering the Proclaim neurostimulation platform, including DRG and SCS implants for chronic pain indications. Comparable in underlying neuromodulation implant technology, though distributed as a device across many clinical specialties rather than as a single dedicated migraine service.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Migraine Centers social profiles
Digital presenceMigraine Centers financial estimates
Financial estimateRevenue estimate
Valuation estimate
Migraine Centers leadership team
Management profileNumber of profiles
Profiles1 record
Migraine Centers funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Migraine Centers M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Migraine Centers
What does Migraine Centers do?
Migraine Centers offers the Omega Procedure®, an FDA-approved neurostimulation therapy for chronic migraines. The treatment involves a two-phase approach: a Trial Phase with temporarily implanted leads (1-2 weeks) to assess efficacy, followed by a Permanent Phase implanting a small battery-powered neurostimulator beneath the skin near the occipital nerve. Patients activate electrical impulses via a remote control to disrupt migraine pain signals before reaching the brain.
Is Migraine Centers a public or private company?
Migraine Centers is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Migraine Centers founded?
Migraine Centers was founded in 2011. It employs 51 to 100 people.
Where is Migraine Centers based?
Migraine Centers is headquartered in Richardson, United States, in the North America region.
How does Migraine Centers make money?
Three revenue lines are on record. Medical Procedure Fees are the primary driver. The others are insurance Billing and consultation Services.
Who are Migraine Centers's main competitors?
Direct peers on record are Diamond Headache Clinic and Jefferson Headache Center (Thomas Jefferson University). Emerging players are axioBionics, Axonics (Boston Scientific), eNeura, Theranica (Nerivio) and Cefaly. Broad incumbents are Medtronic (Pain Therapies), Mayo Clinic Headache Division and Abbott (Proclaim Neurostimulation Systems).
Does Migraine Centers have an API?
No public API is recorded for Migraine Centers.
What industry is Migraine Centers in?
Migraine Centers's product category is Migraine Treatment Services. Its primary akta.pro industry code is HLAKAIAE, Headache & Migraine Medicine, with a secondary code of HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 6219 and its SIC code is 8011.